1. Introduction {#sec0005}
===============

Peripartum cardiomyopathy (PPCM) has been traditionally defined as rare, acquired, idiopathic, non-genetic, non-familial and dilated cardiomyopathy that presents with heart failure secondary to left ventricular systolic dysfunction in last month of pregnancy or first five months after delivery, in the absence of any other cause of heart failure.[@bib0005], [@bib0010], [@bib0015], [@bib0020], [@bib0025] Angiotensin-converting enzyme (ACE) is a zinc metallopeptidase that converts Angiotensin I to Angiotensin II which is a potent vasoconstrictor, stimulates adrenal cortex to release aldosterone which increases plasma volume, mediates cell growth and proliferation by stimulating various cytokines, growth factors and induces endothelial dysfunction by reducing nitric oxide bioavailability. These mechanisms emphasize the importance of angiotensin II in cardiovascular pathophysiology and motivate the exploration of the role of the renin-angiotensin-aldosterone system (RAAS) in cardiovascular pathology. [@bib0030], [@bib0035]

The role of insertion/deletion (I/D) polymorphism of ACE gene and ACE activity in etiology, pathogenesis, prognosis, and other clinical implications in the various form of the cardiovascular disease has been established to some degree of certainty. ACE gene polymorphism in various specific cardiomyopathies like that of ischemic, idiopathic dilated, hypertrophic and alcoholic cardiomyopathy have been studied depicting the positive correlation between the frequency of D allele and development of specific cardiovascular pathophysiology. The fact that idiopathic dilated cardiomyopathy (IDCM), alcoholic cardiomyopathy and other forms of low ejection fraction state bear a phenotypic resemblance to that of PPCM, has prompted us to take on the study of the association of ACE gene I/D polymorphism in patients with PPCM.[@bib0040] We for the first time tested the hypothesis that PPCM may be associated with higher incidence of ACE-DD genotype and overall frequency of D allele and that the DD genotype in cases may be associated with the lower systolic performance of left ventricle.

2. Methods {#sec0010}
==========

2.1. Study design {#sec0015}
-----------------

This was a single centre hospital-based, Case-control study done in Kashmir (A state of north India) and carried out from August 2012 to March 2015

2.2. Study population {#sec0020}
---------------------

CASES: The study population included 45 consecutive Kashmiri patients admitted to our hospital with PPCM diagnosed by clinical (Presentation of heart failure in last month of pregnancy or first 5 months postpartum) and echocardiographic (left ventricular ejection fraction \<0.45 or M-mode fractional shortening \<30% (or both) and end-diastolic dimension \>2.7 cm/m^2^) criteria. Patients with a history of the pre-existing cardiac disease, hypertension (essential or pregnancy induced) or any structural heart disease inconsistent with PPCM on echocardiography and those with multiple gestations were excluded from the study. CONTROLS: A total number of controls were 70. Controls were healthy married normotensive, Kashmiri females, within first five months of puerperium with no history suggestive of cardiac disease, structurally and functionally normal heart (measured echocardiographically) and no history of pregnancy induced hypertension.

2.3. Consent and ethical issues*.* {#sec0025}
----------------------------------

An informed consent was obtained from each subject after explaining the study in detail. The study was cleared by the Institutional Ethics Committee.

2.4. Initial evaluation {#sec0030}
-----------------------

Patient's New York Heart Association (NYHA) functional class was assessed at first contact by thorough interview.[@bib0065] This was followed by complete general physical and specific cardiovascular examination. Standard 12 lead ECG was recorded in all patients and Chest radiography was done in only 31 patients who had presented in the postpartum period in order to avoid radiation exposure to the fetus.

2.5. Echocardiography {#sec0035}
---------------------

A comprehensive echocardiographic examination of patients and controls was carried out using a commercially available cardiac ultrasound scanner equipped with 2.5 and 3.5 MHz transducers (Aloka, Prosound, SSD α-110, South Korea), by an experienced cardiologist. Each patient was examined in the left lateral decubitus and supine position by precordial transthoracic two-dimensional targeted M-mode echocardiography with Doppler color flow mapping. Echocardiographic parameters that were recorded were systolic and diastolic left ventricular dimensions, fractional shortening, diastolic functions by transmitral flow velocities, left ventricular end diastolic volume, end systolic volume and ejection fraction by Simpson's method and left atrial diameter. These measurements taken were strictly according to the joint guidelines by American Society of Echocardiography and European Association of Echocardiography.[@bib0070] Measurements of left ventricular dimensions and function were determined by an average of ≥3 beats. Subjects were categorized as follows on the basis of echocardiographic parameters: Mild LV dysfunction, EF = 41--45, moderate LV dysfunction, EF = 31--40 and severe LV dysfunction, EF ≤ 30. Furthermore, subjects were classified on the basis of severity of LV dilatation as follows: Normal LV end diastolic volume = 56--104 ml; Mild LV dilatation LVEDV, 105--117 ml; Moderate LV dilatation LVEDV, 118--130 ml; and Severe LV dilatation; LVEDV \> 130.[@bib0070]

2.6. Extraction and amplification of genomic DNA {#sec0040}
------------------------------------------------

Blood samples were taken from both the groups after obtaining written informed consent. Five milliliters of peripheral blood was obtained from each subject in ethylenediaminetetraacetic acid (EDTA) containing vials (200 μl of 0.5 M, pH = 8.0) and stored at −20 °C until use. Deoxyribonucleic acid (DNA) extraction from blood sample was performed according to the manufacturer's protocol for Qiagen DNA extraction kits (Qiagen, Hilden, NRW, Germany). DNA content was quantified by spectrophotometric absorption (Nanodrop Spectrophotometer, BioLab, Scoresby, VIC, Australia). Polymerase chain reaction (PCR) was performed using an iCycler Thermal Cycler (Bio-Rad, Hercules, CA, USA). Molecular detection of the ACE I/D polymorphism was performed by PCR amplification of 287-bp sequence of DNA of intron 16. The template DNA (0.5--1.0 μg) was used in a PCR under stringent conditions to avoid the possibility of false positives for ACE genotyping. The reactions was be carried out with 10 pmol of each primer: Forward primer, 5′-CTG GAG ACC ACT CCC ATC CTT TCT-3′, and reverse primer, 5′-GAT GTG GCC ATC TTC GTC AGA T-3′, in a final volume of 25 μl containing 1.5 mM MgCl2, 25 mM KCl, 5 mM Tris-HCl (pH 8.4), 0.25 mM each of deoxyribonucleotide triphosphate (dNTP, Biotools, Spain) and 1 unit Taq polymeRAASe (Biotools, Spain). Amplification was carried out in a DNA thermal cycler (Pamcycler thermocycler) for 30 cycles with denaturation extension at 72 o C for 2 min. The PCR products were separated on a 2% agarose gel and DNA were visualized by ethidium bromide staining. The PCR product is a 490-bp fragment in the presence of the insertion (I) allele. Thus, each DNA sample revealed one of three possible patterns after electrophoresis: A 490-bp band (genotype I/I), a 190-bp band (genotype D/D), or both 490-bp and 190-bp bands (genotype I/D). Restriction fragments were visualized after ethidium bromide staining of the agarose gel with the use of an ultraviolet transilluminator ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Direct visualization of ACE I/D PCR products, electrophoresed on 2% agarose gel, by ethidium bromide staining. A 490 base pair ACE I allele and 190 base pair ACE D allele is seen. Results from 8 patients are shown.II homozygote genotypes: Lane 6 and 8.DD homozygote: Lanes 3, 5 and 7ID heterozygotes: Lane: 1 and 2.Control (D. H~2~O): 4Fig. 1

2.7. Collection and recording of data {#sec0045}
-------------------------------------

All the patient data including demographic, clinical and diagnostic data as well as hospital outcome were recorded on a specially pre-designed patient record form.

2.8. Statistical analysis {#sec0050}
-------------------------

All continuous variables of study have been shown in terms of Mean ± SD and the categorical variables in terms of frequency and percentage. Continuous variables have been compared using T-test and Chi-square test has been used to analyze categorical variables. All the results obtained have been discussed on 5% level of significance with p value \< 0.05 considered as significant. Also suitable statistical charts have been used to represent the data, SPSS version 20 was used for analysis.

3. Results {#sec0055}
==========

3.1. Patient characteristics {#sec0060}
----------------------------

After excluding four patients (with two having associated pregnancy induced hypertension one patient had twin pregnancy and one patient had poor echocardiographic window that precluded the proper assessment), total of 45 patients who met the inclusion criteria, were enrolled in the study. Demographic charactaristics of cases and controls are depicted in [Table 1](#tbl0005){ref-type="table"}. There wasn't significant difference in terms of age and parity between the two groups.Table 1Demographic and clinical characteristics.Table 1CasesControlsAgeMean (years) 31.8 ± 5.19\
Range (years) 22--42Mean (years) 31.48 ± 4.42\
Range (years) 24--40P = NSParityMean 2.56 ± 1.27\
Range 1--6Mean 2.14 ± 0.92\
Range 1--5P = NS  Clinical characteristics of CasesNYHA ClassII*n* = 13 (29%)III*n* = 25 (55.5%)IV*n* = 7 (15.5%)Clinical SignsSystolic BP (mmHg)\
\>90*n* = 33 73.4%\<90*n* = 9 20%\<90 with clinical signs of shock*n* = 3 6.6%Mean Heart rateControls = 83.8 ± 10.4\
Cases = 104.4 ± 16.5P \< 0.05[\*](#tblfn0005){ref-type="table-fn"}Peripheral edema*n* = 29 64.4%Raised JVP*n* = 26 57.7%Murmur*n* = 8 17.8%Clinical S3*n* = 19 42.3%[^1][^2]

3.2. Clinical characteristics {#sec0065}
-----------------------------

NYHA class III was the most common presentation followed by class II and class IV respectively. Breathlessness was present in 91%, nocturnal cough in 51% and palpitations in 26% patients. Most patients had normal blood pressure at presentation (n: 33; 73%), 9 patients (20%) were in hypotension and 3 patients were in clinical shock. There was a significant difference in the mean heart rate between two groups. Chest radiograph was done only in patients presenting postpartum (n = 31) to avoid the radiation exposure to the fetus, out of whom 21 (65.6%) had CTR greater than 5.5.

3.3. Echocardiographic parameters {#sec0070}
---------------------------------

Baseline echocardiographic parameters of the cases and controls are depicted in [Table 2](#tbl0010){ref-type="table"}. There was a significant difference in mean ejection fraction (EF), left ventricular systolic and diastolic indicies between cases and controls. Total of 11 patients (24.4%) had normal left ventricular volume. Eleven cases (24%) had moderate to severe secondary mitral regurgitation ([Fig. 2](#fig0010){ref-type="fig"}).Fig. 2Line diagram showing the frequency of I/D polymorphism in cases vs. controls.Fig. 2Table 2Laboratory characteristics of cases.Table 2Cases*Controls*ControlsECGNormaln = 9; 20%n = 63; 90%Sinus tachycardian = 27;60%n = 7; 10%LBBBn = 5; 11%--Atrial fibrillationn = 4; 8.8%--Chest Xray (done in 31 Patients)Normal CTR*n* = 21;34.4--Increased CTR*n* = 11;65.6--Ejection FractionMean34.24 (±5.84)66.7(±7.0)P \< 0.05[\*](#tblfn0010){ref-type="table-fn"}EF = 41--45*n* = 7 15.5%--EF = 31--40*n* = 28 62.2%--EF ≤ 30*n* = 10 22.3%--LV dimensionsLVEDD (mm)Mean = 59.2 (±7.04)47.4 (±4.6)P \< 0.05[\*](#tblfn0010){ref-type="table-fn"}LVESD (mm)Mean = 47.6 (±7.43)29.6 (±3.5)P \< 0.05[\*](#tblfn0010){ref-type="table-fn"}LV volumesLVESV (ml)Mean = 78.8 (±22.6)34.5(±9.8)P \< 0.05[\*](#tblfn0010){ref-type="table-fn"}LVEDV (ml)Mean = 120 (±26.24)105.7 (±23.8)P \< 0.05[\*](#tblfn0010){ref-type="table-fn"}Severity of LV dilatation (Cases)Normal*n* = 11 24.4%--Mild dilatation*n* = 13 28.9%--Moderate dilatation*n* = 11 24.4%--Severe dilatation*n* = 10 22.3%--[^3][^4][^5]

3.4. ACE genotype {#sec0075}
-----------------

The ACE genotype was determined in 45 patients with PPCM and compared with 70 controls. The results are shown in [Table 3](#tbl0015){ref-type="table"}. When mean EF, mean of left ventricular end diastolic and end systolic diameters and volume of cases with II + ID genotype was compared with that of DD genotype, later had worse parameters but same was not statistically significant ([Table 4](#tbl0020){ref-type="table"}). Mean left atrial size didn't differ much between the two groups.Table 3Comparison of ACE I/D genotype in cases vs. controls.Table 3CasesControlsOdds ratio95% CI*P* valueII16 (35.5%)48 (68.5%)0.2530.114--0.558**0.007**ID18 (40%)19 (27.1%)1.930.86--4.30.107DD11 (24.4%)3 (4.3%)7.2251.88--27.6**0.0039**I50(55.5%)115 (82.1%)0.270.14--0.49**0.0001**D40(44.4%)25 (17.9%)4.252.01--6.7**0.0001**[^6]Table 4LV systolic functions, LV size, LV volume and LA size in DD genotypes vs II + ID genotypes combined.Table 4Females with DD genotypeFemales with II + ID genotypeP^\*^Mean EF32.335.30.194Mean LVEDD in mm61.158.50.306Mean LVESD in mm49.7470.346Mean LVEDV in ml126.8119.260.594Mean LVESV in ml8777.390.409Mean LA size in mm40.638.20.279[^7]

4. Discussion {#sec0080}
=============

The main findings of our study were:1.ACE-DD genotype was statistically significant in patients with PPCM2.Overall frequency of D allele was significantly higher in cases3.DD genotype was associated with worse systolic performance indices in terms of ejection fraction, LV end-systolic and end-diastolic dimensions and volumes.

The renin-angiotensin system (RAAS) plays a central role in cardiovascular homeostasis. Angiotensin is the key peptide of the RAAS and exerts its influence on the heart and blood vessels both through its hemodynamic effects (via its influence on after-load and pre-load and determining coronary vasoconstriction) and through its direct cellular effects (via its actions on cell proliferation).[@bib0035] The discovery that ACE levels are under genetic control ushered in a new era of investigation; most studies focused on an insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene as a marker for a functional polymorphism. In 1990, Rigat and coworkers published an important report that provided the impetus to further study polymorphisms in this gene.[@bib0045] They found a polymorphism involving the presence (insertion, I) or absence (deletion, D) of a 287-bp sequence of DNA in intron 16 of the gene. Mean ACE activity levels in DD carriers were approximately twice that found in II genotype individuals.[@bib0050] Subjects with the ID genotype had intermediate levels indicating codominance. The I/D polymorphism accounted for approximately half (47%) of the observed variance in ACE levels in this study group. Later studies showed that the involvement of the I/D polymorphism is not limited to ACE levels in plasma, and is also detected in tissue ACE levels. [@bib0050], [@bib0055]

Although there is no reported study regarding ACE-gene I/D polymorphism in PPCM, various cardiovascular abnormalities bearing phenotypic resemblance to that of PPCM have shown a positive correlation with D allele and specific cardiomyopathy. In our study, we could establish a positive association between subjects with PPCM with DD genotype and D allele of ACE gene, which is in consistency with many other studies primarily involving cardiac muscle. Raynolds et al. determined the genotypes of individuals with end-stage heart failure due to either ischaemic dilated cardiomyopathy or idiopathic dilated cardiomyopathy and compared these to organ donors with normally functioning hearts. Compared with the DD frequency in the control population, the frequency of the ACE DD genotype was 48% higher in individuals with idiopathic dilated cardiomyopathy (p = 0.008) and 63% higher in subjects with ischaemic cardiomyopathy (p = 0.008), suggesting that an ACE gene variant may contribute to the pathogenesis of both types of cardiomyopathy.[@bib0060] Mahjoub et al. found a similar result in Tunisian population with dilated cardiomyopathy. They concluded that frequencies of the DD genotype and D allele were significantly higher in patients with dilated cardiomyopathy as compared with controls.[@bib0065] Another form of myocardial disease like hypertrophic cardiomyopathy and alcoholic cardiomyopathy has also been shown to have an association with DD genotype and with a higher frequency of D allele.[@bib0070], [@bib0075], [@bib0080] In our study, we could establish a positive association between DD genotype and D allele of ACE gene in subjects with PPCM which is in consistency with many other studies involving primarily cardiac muscle.

We also found that echocardiographically determined left ventricular systolic performance indices were affected by ACE I/D polymorphism. Mean LV-ejection fraction was lower and mean of LV linear dimension and volume was higher in cases with DD genotype when compared with combined mean of cases with ID and II genotype. Previous studies have almost consistently shown worse echocardiographic systolic performance indices (EF, LV dimensions, and volumes) as well as overall prognosis with DD genotype in other phenotypically similar cardiomyopathies.[@bib0085], [@bib0090], [@bib0095] Moreover, patients with DD genotype have shown to get maximum benefit from pharmacological ACE antagonism.[@bib0100] This observation may have implication on patients of PPCM as they are usually denied the beneficial effects of ACE inhibitors late in pregnancy owing to deleterious effects on the fetus.

Although exact etiology and pathogenesis of PPCM are an active area of research, our study may open the new dimensions in this area. Moreover, studies have conclusively shown that long-term inhibition of Renin-Angiotensin by various drugs started early in the course of the disease in other phenotypically similar forms of cardiomyopathy alters the natural course and promotes reverse remodeling of left ventricle, same benefit may, however, be denied in this specific form of cardiomyopathy as inhibitors of Renin-Angiotensin system in late pregnancy (when pathophysiology of this disease entity usually starts) are absolutely contraindicated. The development of so-called "Pregnancy safe ACE inhibitor or ARB" may have a protective role, halt or reverse the disease progression in such cases.

Owing to the rarity of the disease, the number of patients in our study was relatively small, therefore results might be open to interpretation, a clear interrelation between genotypes and PPCM could nonetheless be seen. Further population-based, multicenter studies over longer periods involving multiple geographic regions and different ethnic groups should be done. Also, longitudinal follow-up studies where long-term prognosis and recovery of left ventricular functions in different genetic groups of ACE-gene need to be carried out.

5. Conclusion {#sec0085}
=============

This case-control study has demonstrated that the ACE DD genotype and overall frequency of D allele is significantly higher in patients with PPCM. Thus, the presence of D allele and DD genotype may predispose and may be an independent risk factor for the development of PPCM. Also presence of ACE-gene DD genotype in our study is associated with worse left ventricular performance. Further studies, however, need to be undertaken with a larger number of patients taking region and ethnicity into account.

6. Study limitations {#sec0090}
====================

•The major limitation of this study is the small sample size owing to the low prevalence of PPCM in our community. This has resulted in wide confidence intervals and lower statistical power of the study.•Moreover, our study comprised of the single ethnic population, the polymorphism of ACE genotype may vary in different regions of the world.•We did not study the long term follow-up of these patients. Polymorphism of ACE gene may have implications on overall prognosis in PPCM. Longitudinal studies studying the death, hospitalisations for heart failure and recovery of LV functions in correlation with I/D polymorphism of ACE gene need to be put into perspective.
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[^1]: NYHA = New York heart association; JVP = jugular venous; BP = Blood Pressure; ECG = Electrocardiogram; CTR = Cardiothoracic ratio.

[^2]: P value significant.

[^3]: EF = ejection fraction; LVEDD = left ventricular end diastolic diameter; LVESD = left ventricular end systolic diameter; LV = left ventricle; *Recommendations of report from American Society of Echocardiography's in conjunction with European Association of Echocardiography, a branch of ESC*. \[\* Normal LV end diastolic volume; 56--104 ml, Mild LV dilatation LVEDV; 105--117 ml, Moderate LV dilatation LVEDV; 118--130 ml, Severe LV dilatation; LVEDV \> 130.[@bib0070]

[^4]: EF was calculated by Simpson's method.

[^5]: Significant P value.

[^6]: Bold values represent significant *p* value.

[^7]: ^\*^P \< 0.05 is statistically significant.
